Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Revenue projections:

Revenue projections for GLENMARK
Revenue projections for GLENMARK

GLENMARK's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 1.646000
forwardPE 24.089176
debtToEquity 12.776000
earningsGrowth 0.723000
revenueGrowth 0.761000
grossMargins 0.710880
operatingMargins 0.366860
trailingEps 35.810000
forwardEps 42.480000

GLENMARK's current ratio of 1.646 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring GLENMARK is unlikely to face difficulties in meeting immediate financial obligations.
Glenmark Pharmaceuticals Limited's Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
Glenmark Pharmaceuticals Limited's low Debt-to-Equity ratio demonstrates that the company maintains a healthy balance between equity and debt, avoiding over-leverage. This suggests a low-risk financial profile, giving investors confidence in the company's stability and ability to manage its financial commitments.
Positive earnings and revenue growth for GLENMARK suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
Positive gross and operating margins for GLENMARK suggest that the company is operating profitably. These margins highlight GLENMARK's efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.
GLENMARK's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for GLENMARK's financial growth.

Price projections:

Price projections for GLENMARK
Price projections for GLENMARK

The price of GLENMARK has consistently been close to the lower limit of expectations. This trend may point to challenges in the company's performance, leading to concerns about its future growth potential.

Recommendation changes over time:

Recommendations trend for GLENMARK
Recommendations trend for GLENMARK


A recent buy bias from analysts toward GLENMARK indicates strong confidence in the stock's future performance. This could encourage investors to park their money in GLENMARK, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.